–Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson’s disease
–Additional poster presentations planned on the real-world efficacy and safety of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and cervical dystonia
–Research highlights AbbVie’s continued focus on advancing the management of movement disorders
NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented.
“At AbbVie, we are committed to addressing the unmet needs of people living with a wide range of movement disorders,” said Sebastian Sorsaburu, MD, vice president, global specialty care medical affairs, AbbVie. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”
Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.
Key AbbVie abstracts for the MDS Virtual Congress 2021, which will all be available as virtual e-posters beginning at 8:00 a.m. CDT on September 10, are outlined below.
| Key AbbVie Abstracts at MDS 2021 |
| Abstract Title |
| DUODOPA® Abstracts |
| Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis from the DYSCOVER Study |
| Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up |
| Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients with Motor Fluctuations and Dyskinesia Managed with Oral Dopaminergic Therapies Versus Device-Aided Therapies |
| Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study |
| Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients with Advanced Parkinson’s Disease |
| Long-Term Real-World Effectiveness of Carbidopa/Levodopa Enteral Suspension After 36 Months of Treatment Initiation: Final Results from PROviDE Study |
| Levodopa/Carbidopa Intestinal Gel (LCIG) Reduces Fluctuations and Shortens Time to On Without Troublesome Dyskinesia in Advanced Parkinson’s Disease: Post-Hoc Analyses of 54-week LCIG-Monotherapy Trial |
| Real-World Characteristics of Advanced Parkinson’s Disease Patients Initiating Carbidopa/Levodopa Enteral Suspension |
| Impact of Device-Aided Therapies on QoL and Off-Time Improvement in Advanced Parkinson’s Disease Patients: Comparative Effectiveness Results from a Bayesian Network Meta-Analysis |
| Overview of the Population of Patients with Advanced Parkinson’s Disease (aPD) Initiating Therapy with Levodopa-Carbidopa Intestinal Gel (LCIG): POMPE-PARK Study on French Health Insurance Data (2013-2017) |
| BOTOX® Abstracts |
| OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study |
| Neutralizing Antibody Conversion with OnabotulinumtoxinA from Global Studies Across Multiple Indications with a Focus on Movement Disorders: A Meta-Analysis |
| Benefits of Treatment with OnabotulinumtoxinA in Naive and Non-Naive Patients with Cervical Dystonia are Sustained Over Time: Preliminary Completer Analysis from CD PROBE |
| Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population |
| A Cell-Penetrating Peptide (CPP) Did Not Decrease 150-kDa BoNT/A Toxin Adsorption to Surfaces or Increase Toxin Potency or Duration in a Prototype Formulation |
| OnabotulinumtoxinA Exhibits Greater Efficacy Compared to Purified Botulinum Neurotoxin A (Bont/A-150 KDA) in Peripheral Pain Models |
| Disease State Abstracts |
| Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool |
| COVID-19 Pandemic Impact on Advanced Parkinson’s Disease in the US |
| Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians |
